Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

EXACT Sciences Says It Submitted Final Module Of PMA For Cologuard To The FDA

RELATED NEWS
Trade EXAS now with 

EXACT Sciences Corp. (EXAS: Quote), a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, Monday said that it submitted the final module of the premarket approval or PMA for Cologuard, the company's stool DNA or sDNA colorectal cancer screening test, to the U.S. Food and Drug Administration or FDA. The final module which was submitted on June 7, comprised of data from the company's DeeP-C clinical trial. The trial analyzed data from about 10,000 patients at 90 sites between the ages of 50 and 84 who were at average risk for colorectal cancer.

EXACT Sciences also announced that the role of COO Maneesh Arora would now also include the oversight of U.S. sales and marketing. The company is also in the search for a senior financial officer.

Click here to receive FREE breaking news email alerts for EXACT Sciences Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Kraton Performance Polymers, Inc. (KRA), Wednesday reported second-quarter net income of $11.1 million or $0.33 per share, up from $3.8 million or $0.12 per share last year. Adjusted earnings improved to $0.46 per share from $0.15 per share last year. Revenues for the quarter dropped to $323.8... Organic grocer Whole Foods Market, Inc. said Wednesday after the markets closed that its third quarter profit rose 6.3% from last year, as same-store sales increased 3.9%. The company's quarterly earnings per share also came in above analysts' expectations, but its quarterly sales fell shy of analyst' forecast. Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.